新型3-吡咯烷吲哚衍生物作为5-羟色胺能致幻剂用于治疗精神病以及抑郁症和创伤后应激障碍等精神疾病。
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
Abstract
Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.
摘要
本文提供了作为血清素能致幻剂的新型3-吡咯烷吲哚衍生物、药物组合物、此类化合物在治疗精神病和精神疾病（如抑郁症和创伤后应激障碍）中的用途，以及制备此类化合物的方法。
相似文献
1
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.新型3-吡咯烷吲哚衍生物作为5-羟色胺能致幻剂用于治疗精神病以及抑郁症和创伤后应激障碍等精神疾病。
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
2
Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.新型吲哚啉衍生物作为用于治疗精神病、精神疾病和中枢神经系统疾病的血清素能致幻剂。
ACS Med Chem Lett. 2025 Jan 23;16(2):196-197. doi: 10.1021/acsmedchemlett.5c00004. eCollection 2025 Feb 13.
3
Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.新型吲哚衍生物作为用于治疗精神病、精神疾病和中枢神经系统疾病的血清素能致幻剂。
ACS Med Chem Lett. 2025 May 30;16(6):982-983. doi: 10.1021/acsmedchemlett.5c00309. eCollection 2025 Jun 12.
4
Positive Symptoms of Psychosis and International Classification of Diseases 11th Revision (ICD-11) Complex Post-traumatic Stress Disorder: A Network Analysis in a Canadian Sample from Montreal: Symptômes positifs de psychose et trouble de stress post-traumatique complexe (CIM-11): Une analyse de réseau dans un échantillon canadien de Montréal.精神病的阳性症状与《国际疾病分类第11版》（ICD - 11）复杂性创伤后应激障碍：来自蒙特利尔的加拿大样本的网络分析：精神病阳性症状与复杂性创伤后应激障碍（ICD - 11）：蒙特利尔加拿大样本的网络分析
Can J Psychiatry. 2025 May 15:7067437251337645. doi: 10.1177/07067437251337645.
5
Post-traumatic stress disorder in psychedelic research.迷幻药研究中的创伤后应激障碍
Int Rev Neurobiol. 2025;181:329-355. doi: 10.1016/bs.irn.2025.02.004. Epub 2025 Jun 12.
6
Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.创伤后应激障碍及共病物质使用障碍的心理治疗
Cochrane Database Syst Rev. 2016 Apr 4;4(4):CD010204. doi: 10.1002/14651858.CD010204.pub2.
7
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.致幻剂辅助治疗对患有危及生命疾病的人群的焦虑、抑郁和存在性困扰的治疗作用。
Cochrane Database Syst Rev. 2024 Sep 12;9(9):CD015383. doi: 10.1002/14651858.CD015383.pub2.
8
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.新型咪唑并吡啶和咪唑并哒嗪衍生物作为治疗多种疾病的二酰甘油酰基转移酶2（DGAT2）抑制剂
ACS Med Chem Lett. 2024 Jul 3;15(8):1180-1181. doi: 10.1021/acsmedchemlett.4c00286. eCollection 2024 Aug 8.
9
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.新型咪唑并三嗪衍生物作为治疗炎症和自身免疫性疾病的白细胞介素-17调节剂
ACS Med Chem Lett. 2024 Dec 10;16(1):12-13. doi: 10.1021/acsmedchemlett.4c00573. eCollection 2025 Jan 9.
10
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
引用本文的文献
1
Novel Compounds as 5-HT2A Receptor Modulators for Treating Psychiatric and Neurological Disorders.作为用于治疗精神和神经疾病的5-HT2A受体调节剂的新型化合物。
ACS Med Chem Lett. 2025 Mar 13;16(4):508-509. doi: 10.1021/acsmedchemlett.5c00093. eCollection 2025 Apr 10.
2
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.作为用于治疗精神疾病或中枢神经系统疾病的5-HT2A激动剂的新型化合物。
ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.
3
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
4
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.作为用于治疗精神疾病的5-HT2A激动剂的新型吡咯并吡啶化合物。
ACS Med Chem Lett. 2025 Jan 23;16(2):202-203. doi: 10.1021/acsmedchemlett.5c00019. eCollection 2025 Feb 13.
5
Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.新型吲哚啉衍生物作为用于治疗精神病、精神疾病和中枢神经系统疾病的血清素能致幻剂。
ACS Med Chem Lett. 2025 Jan 23;16(2):196-197. doi: 10.1021/acsmedchemlett.5c00004. eCollection 2025 Feb 13.
6
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
本文引用的文献
1
1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review.1-（2,5-二甲氧基-4-碘苯基）-2-氨基丙烷（DOI）：从一种鲜为人知的物质到血清素致幻剂DOX家族的关键成员——综述
ACS Pharmacol Transl Sci. 2024 May 8;7(6):1722-1745. doi: 10.1021/acsptsci.4c00157. eCollection 2024 Jun 14.
2
Psychedelic therapy in depression and substance use disorders.致幻剂治疗抑郁症和物质使用障碍。
Eur J Neurosci. 2024 Jul;60(2):4063-4077. doi: 10.1111/ejn.16421. Epub 2024 May 21.
3
The role of serotonin in depression-A historical roundup and future directions.血清素在抑郁症中的作用——历史综述及未来方向
J Neurochem. 2024 Sep;168(9):1751-1779. doi: 10.1111/jnc.16097. Epub 2024 Mar 13.
4
Serotonin 2A Receptor (5-HTR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.血清素2A受体（5-羟色胺受体）激动剂：作为新型抗抑郁药的致幻剂和非致幻类似物
Chem Rev. 2024 Jan 10;124(1):124-163. doi: 10.1021/acs.chemrev.3c00375. Epub 2023 Nov 30.
Zotero 插件